February started emphatically at the US FDA, with novel approvals from both the drugs and biologics centers, including the first biologic with a Regenerative Medicine Advanced Therapy (RMAT) designation to reach approval. (See sidebar for story on approval of Bristol Myers Squibb Company’s CAR-T therapy Breyanzi.)
The Center for Drug Evaluation and Research opened the month with two targeted oncology approvals, TG Therapeutics, Inc.’s Ukoniq...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?